New Two-Pronged Cancer-Fighting cell therapy enters first human safety trial
NCT ID NCT07335328
Summary
This is a first-in-human study to test the safety of a new type of CAR-T cell therapy for adults with B-cell cancers like lymphoma that have come back or stopped responding to other treatments. The therapy uses a patient's own modified immune cells designed to attack cancer by targeting two proteins (CD19 and CD20) at once. The main goal is to find the highest safe dose and understand the side effects in a small group of up to 24 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.